Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Cardiol Therapeutics in a research note issued on Monday, June 2nd. HC Wainwright analyst B. Folkes expects that the company will earn ($0.12) per share for the quarter. HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics' Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.50) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at $0.40 EPS and FY2029 earnings at $0.97 EPS.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01.
Cardiol Therapeutics Trading Up 2.2%
Shares of Cardiol Therapeutics stock traded up $0.03 during trading hours on Wednesday, reaching $1.41. The stock had a trading volume of 173,836 shares, compared to its average volume of 354,751. The firm has a market capitalization of $116.48 million, a price-to-earnings ratio of -3.62 and a beta of 1.03. Cardiol Therapeutics has a 1 year low of $0.77 and a 1 year high of $3.12. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $1.08 and a two-hundred day simple moving average of $1.22.
Hedge Funds Weigh In On Cardiol Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers purchased a new position in Cardiol Therapeutics in the fourth quarter valued at about $56,000. Virtu Financial LLC purchased a new position in Cardiol Therapeutics in the fourth quarter valued at about $61,000. Envestnet Asset Management Inc. purchased a new position in Cardiol Therapeutics in the fourth quarter valued at about $398,000. Atria Investments Inc acquired a new stake in Cardiol Therapeutics in the fourth quarter valued at approximately $174,000. Finally, PVG Asset Management Corp acquired a new stake in Cardiol Therapeutics in the fourth quarter valued at approximately $624,000. Institutional investors and hedge funds own 12.49% of the company's stock.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
See Also
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
